This title participates in our Automatic Subscription Renewal Program
Prices for future subscriptions will be at then prevailing rates.
Auto renewal ensures that our customers are always up-to-date with the most critical information and new developments in their fields as well as continuing to receive updates to our products without interruption of service.
By enrolling your product(s) in our Automatic Subscription Renewal Program, subscriptions automatically renew at the end of the term without any further action on your part, until you cancel your participation in the auto-renew program.
Should you decide for any reason that you no longer wish to be enrolled in the automatic renewal program, or you did not intend to enroll, you may cancel at any time. You can cancel by calling Customer Service at 1.800.638.3030 or emailing [email protected].
Under the Automatic Subscription Renewal Program, all subscriptions are renewed at one-year increments. If you want to be auto-renewed with a multi-year subscription, call Customer Service at 1.800.638.3030. You are not required to renew any minimum number of times.
The cost of the renewal will be the subscription price in effect at the time of each renewal including applicable sales tax and shipping and handling charges. Subscription renewal prices are subject to increase in the future.
Enrolling a subscription product under our automatic renewal program does not affect our cancellation policy. If you have any questions on our cancellation policy, please call Customer Service at 1.800.638.3030 or emailing [email protected].
I read and understand the auto-renew terms and conditions.
Get quick, portable access to the evidence you need to make effective clinical decisions! Evidence-Based Cardiology succinctly summarizes all the clinical trials that affect the practice of cardiovascular medicine, making it easy for you to implement the most appropriate diagnostic tests and treatments for your patients.
Apply the latest knowledge on atrial fibrillation and heart failure, including novel anticoagulants, new medical therapies, new devices including ablation and resynchronization and other advanced therapies.
Select the best interventions for acute coronary syndrome with coverage of new antiplatelet strategies, management strategy updates, and significant data on outcomes and guideline adherence.
Navigate controversies across your entire field with in-depth chapters exploring all areas of preventive cardiology, coronary revascularization and percutaneous procedures, unstable angina/non-ST elevation myocardial infarction, ST-elevation myocardial infarction, heart failure, and arrhythmias.
Look up all essential randomized clinical trials and understand their implications with concise summaries of trial design, study population, treatment regimen, and results, together with relevant ACC/AHA Practice Guidelines.
Now included with the print edition, enjoy the bundled interactive eBook edition, which can be downloaded to your smartphone or tablet, or accessible online and includes features like:
Complete content with enhanced navigation
A powerful search that pulls results from content in the book, your notes, and even the web
Cross-linked pages, references, and more for easy navigation
Highlighting tool for easier reference of key content throughout the text
Ability to take and share notes with friends and colleagues
Quick reference tabbing to save your favorite content for future use
Edition
4
ISBN/ISSN
9781496375117
Product Format
Vitalsource Interactive eBook
Trim Size
5 x 8
Pages
540
Illustration
17
Table
6
Edition
4
Publication Date
August 23, 2016
Benjamin A. Steinberg MD
Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD
Christopher P. Cannon MD
Associate Professor of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA
CONTENTS Preface Contributors
CHAPTER 1. Preventive Cardiology: Risk Factors for Coronary Artery Disease and Primary and Secondary Prevention Christopher P. Cannon, Benjamin A. Steinberg, and Alexander C. Fanaroff CHOLESTEROL AND LIPIDS Epidemiology ACC/AHA Guidelines Drugs' Bile Resins (e.g., Cholestyramine, Colestipol) Fibric Acid Derivatives (e.g., Gemfibrozil, Fenofibrate) Cholesterol Absorption Inhibitors 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors (Statins) Primary Prevention Trials Secondary Prevention Trials Combined Primary And Secondary Prevention Trials Early Statin Initiation Trials Raising HDL Cholesterol Niacin Cholesterol Ester Transfer Protein Inhibitors DIET AND VITAMINS Special Diets Alcohol LIFESTYLE FACTORS Obesity Exercise Smoking METABOLIC SYNDROME DIABETES HYPERTENSION Epidemiology Etiology Diagnosis Treatment' Non-Pharmacologic Pharmacologic Target Blood Pressure NON-MODIFIABLE RISK FACTORS Family History Age Gender Genetic Markers HORMONAL STATUS AND HORMONAL THERAPY INFLAMMATION C-Reactive Protein Homocysteine and B Vitamins Lipoprotein-Associated Phospholipase A2 Infections and Cardiovascular Disease ANTIPLATELET DRUGS FOR PRIMARY AND SECONDARY PREVENTION Aspirin' Primary Prevention Trials Secondary Prevention Trials Clopidogrel REFERENCES General Articles Lipids And Cholesterol' Guidelines Epidemiology Primary Prevention Early Trials Statins In Primary Prevention Combination Therapy In The Statin Era Secondary Prevention Placebo-Controlled Trials Intensive- Versus Standard-Dose Statin Regimens In Stable CAD Early Statin Initiation In ACS Combined Primary And Secondary Prevention Trials Primary And Secondary Prevention Trials In Patients With Comorbidities Meta-Analyses and Non-Cholesterol Effects of Statins HDL-Raising Therapies Niacin CETP Inhibitors Meta-Analyses And General Studies Novel Classes of Lipid-Lowering Agents Antioxidants, Vitamins, Fish Oil, Chelation, Hormones' Observational Studies Clinical Trials Meta-Analyses Diet' Observational Studies Clinical Trials Alcohol Lifestyle' Guidelines and General Articles Obesity And Weight Loss Exercise Smoking Epidemiology Smoking Cessation Metabolic Syndrome and Diabetes' Epidemiology Treatment Hypertension' Epidemiology and Risk Factors Studies of Treatment Non-Pharmacologic Therapies Medical Therapy Diabetes And Hypertension Invasive Therapies Meta-Analyses Non-Modifiable Risk Factors' Age and Genetics Inflammation' C-Reactive Protein Homocysteine and B Vitamins Observational Studies Trials And Meta-Analyses Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Infections and Cardiovascular Disease Antibiotic Trials HIV-Related Cardiovascular Risk Miscellaneous Antiplatelet Drugs For Primary And Secondary Prevention' Primary Prevention Secondary Prevention General Review Articles and Meta-Analyses
CHAPTER 2. Coronary Revascularization and Percutaneous Procedures Christopher P. Cannon, Benjamin A. Steinberg, and Justin M. Dunn CORONARY ANGIOGRAPHY Indications Flow Grade Stenosis Morphology PERCUTANEOUS CORONARY INTERVENTION Uses and Indications Operator and Hospital Volume Procedural Details' Access Contrast Agent Lesion Evaluation Balloon Angioplasty Stenting Medications' Aspirin Heparin Low-Molecular-Weight Heparin (LMWH) Direct Thrombin Inhibitors Thienopyridines/Adp Receptor Antagonists Glycoprotein II>IIA Inhibitors Abciximab (Reopro) Eptifibatide (Integrilin) Tirofiban (Aggrastat) Applications of PCI' Stable Angina Unstable Angina/Non–ST Elevation Myocardial Infarction Acute ST-Elevation Myocardial Infarction After Thrombolytic Therapy Stenting Versus Percutaneous Transluminal Coronary Angioplasty: Major Trials Direct Stenting Versus Balloon Predilatation Repeated Intervention Complications' Early Complications Later Complications Stent Thrombosis Restenosis Renal Dysfunction Other Postprocedural Complications Treatment and Prevention of Restenosis' Drug Studies Radiation Therapy Drug-Eluting Stents Directional Atherectomy Rotational Atherectomy Prevention of Distal Embolization' Thrombectomy Distal Protection CORONARY ARTERY BYPASS SURGERY Coronary Artery Bypass Surgery versus Medical Therapy Coronary Artery Bypass Surgery versus Percutaneous Coronary Intervention Internal Mammary Artery Saphenous Vein Grafts TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) Balloon-Expandable TAVR Self-Expanding TAVR REFERENCES Guidelines and Classification Operator and Hospital Characteristics Catheterization Technique Contrast Agents Lesion Evaluation (Fractional Flow Reserve, Intravascular Ultrasound) Comparison of Revascularization with Medical Therapy Stent Studies' Early Stent Comparisons Provisional Stenting Direct Stenting Drug-Eluting Stents Additional Devices/Techniques' Cutting Balloon Atherectomy Studies Radiation Therapy Thrombectomy Distal Protection Adjunctive Pharmacologic Therapy' Aspirin Heparin Low-Molecular-Weight Heparin Thienopyridines Glycoprotein II>IIA Inhibitors Thrombin Inhibitors Special Situations' Chronic Total Occlusions Bypass Graft Lesions Small Vessels Diabetes Complications' Postintervention CK/CK-MB And Troponin Studies Stent Thrombosis Other Complications Coronary Restenosis' Repeat Percutaneous Coronary Intervention For Restenosis After Percutaneous Transluminal Coronary Angiography Effect Of Stent Design Drug Studies Coronary Artery Bypass Graft Surgery' Coronary Artery Bypass Graft Surgery Versus Medical Therapy Coronary Artery Bypass Graft Surgery Versus Percutaneous Transluminal Coronary Angiography Graft And Patency Transcatheter Aortic Valve Replacement (TAVR)
CHAPTER 3. Unstable Angina/Non-ST Elevation MI Christopher P. Cannon, Benjamin A. Steinberg, Matthew W. Sherwood EPIDEMIOLOGY PATHOPHYSIOLOGY CLASSIFICATION Unstable Angina Non–ST Elevation Myocardial Infarction CLINICAL AND LABORATORY FINDINGS History and Symptoms Electrocardiogram Cardiac Enzymes' Creatine Kinase And Creatine Kinase-MB Troponins T And I Myoglobin Estimation Of Early Risk At Presentation TREATMENT Aspirin ADP Receptor Antagonists PAR-1 Receptor Antagonists Heparin Low-Molecular-Weight Heparins Direct Thrombin Inhibitors Factor XA Inhibitors Glycoprotein II>IIA Inhibitors' Intravenous Agents Oral Agents Thrombolytic Therapy Anti-Ischemic Medications' β-Blockers Nitrates Calcium-channel Blockers 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors (Statins) Invasive Strategy' Coronary Artery Bypass Graft Surgery NONINVASIVE EVALUATION Exercise Treadmill Test Exercise Treadmill Testing With Nuclear Imaging Pharmacologic Stress Testing With Imaging Echocardiography Coronary Computerized Tomography Angiography PROGNOSIS AND BIOMARKERS Unstable Angina Non–St Elevation Myocardial Infarction Prior Aspirin Use (Aspirin Failures) Electrocardiography Troponin Levels C-Reactive Protein B-Type Natriuretic Peptide REFERENCES Review Articles and Pathophysiology Drugs and Studies' Aspirin Thienopyridines PAR-1 Receptor Antagonists Unfractionated Heparin And Warfarin Low-Molecular-Weight Heparins Anti-Ischemic Medications Direct Thrombin Inhibitors Factor Xa Inhibitors Glycoprotein II>IIA Inhibitors Thrombolytics Invasive versus Conservative Management Non-Invasive Assessment and Prognosis' Clinical Or General Analyses Biomarkers' Review Articles And Multimarker Studies Troponins High Sensitivity Troponins Inflammatory Markers B-Type Natriuretic Peptide Specific Tests: Angiography, ECG, And Holter
CHAPTER 4. ST-Elevation Myocardial Infarction Christopher P. Cannon, Benjamin A. Steinberg, and Justin M. Dunn EPIDEMIOLOGY PATHOGENESIS DIAGNOSIS Chest Pain Electrocardiography Echocardiography Biomarkers TREATMENT Aspirin P2Y12 Inhibitors' β-Blockers Angiotensin-Converting Enzyme Inhibitors Aldosterone Antagonism Thrombolytic Therapy' Indications For Thrombolysis Contraindications Common Fibrinolytic Agents Streptokinase Tissue Plasminogen Activator Reteplase Tenecteplase Prognostic Indicators Percutaneous Coronary Intervention' Primary Angioplasty Procedural Volume Primary Angioplasty versus Thrombolysis Rescue Angioplasty Routine PCI (After Thrombolysis) Versus Delayed or Conservative Management Facilitated Percutaneous Coronary Intervention Cardiogenic Shock Stenting In STEMI Antithrombotic Regimens' Heparin Enoxaparin Fondaparinux Direct Thrombin Inhibitors Oral Anticoagulants Intravenous Glycoprotein II>IIA Inhibitors Use in Primary PCI Glycoprotein II>IIa Inhibition plus Reduced-Dose Thrombolysis Other Therapies' Nitrates Calcium-Channel Blockers Antiarrhythmics Magnesium Glucose–Insulin–Potassium Intra-Aortic Balloon Pump RIGHT VENTRICULAR INFARCTION Diagnosis Complications Treatment COMPLICATIONS OF STEMI Early Intermediate Late PROGNOSIS AND RISK STRATIFICATION AFTER MYOCARDIAL INFARCTION Uncomplicated STEMI Complicated Course Specific Tests REFERENCES General Review Articles and Guidelines Epidemiology Pathogenesis Diagnosis' Chest Pain And Symptoms Electrocardiography Biomarkers Pre-Hospital And Emergency Department Evaluation Treatment' Aspirin P2Y12 Inhibitors β-Blockers Angiotensin-Converting Enzyme Inhibitors Reviews and Meta-Analyses Studies Thrombolytic Therapy Review Articles and Meta-Analyses Thrombolytic Comparative Studies Prehospital Thrombolysis Studies Percutaneous Coronary Intervention Reviews Meta-Analyses Primary PCI PCI After Thrombolysis Rescue PCI Operator and Hospital Volumes Stenting in STEMI Antithrombotic Regimens Antithrombins Direct Thrombin Inhibitors Oral Anticoagulants Glycoprotein II>IIa Inhibitors Glycoprotein II>IIa Inhibitors And Reduced-Dose Thrombolysis Other Therapies Nitrates Calcium-Channel Blockers Antiarrhythmics Magnesium Glucose–Insulin–Potassium (GIK) Infarct Types Left Ventricular Infarctions Right Ventricular Infarction Treatment Of Cardiogenic Shock Percutaneous Assist Devices Assessment And Prognosis' Reviews And Meta-Analyses Electrocardiography, Arrhythmias, And Conduction Disease Exercise Testing Echocardiography And Other Noninvasive Tests Flow, Vessel Patency, And Angiography Other Prognostic Factors Complications Of Myocardial Infarction' Arrhythmias, Bundle Branch Block Cardiac Rupture Intracranial Hemorrhage In Thrombolysis Reocclusion,Recurrent Ischemia, And Reinfarction Left Ventricular Thrombi Valvular Damage And Septal Defects
CHAPTER 5. Heart Failure Benjamin A. Steinberg and Christopher P. Cannon EPIDEMIOLOGY HISTORY AND PHYSICAL EXAMINATION ETIOLOGY DIAGNOSTIC TESTING TREATMENT Treatment of Acute Heart Failure Treatment of Chronic Heart Failure' Angiotensin-Converting Enzyme Inhibitors Angiotensin II–Receptor Antagonists Dual Ras Blockade (ACE/ARB) β-blockers Diuretics Aldosterone Blockers Digoxin Vasodilators Hydralazine and Isosorbide Dinitrate Calcium-channel Blockers Amiodarone Emerging Medical Therapies Biventricular Pacing Surgical Therapies Left Ventricular Assist Device Coronary Artery Bypass Graft Surgery Cardiac Transplantation Other Surgical Treatments Additional Therapeutic Considerations' Hemodynamic Monitoring Exercise Training And Rehabilitation Prevention Of Sudden Cardiac Death REFERENCES Guidelines and Reviews Epidemiology Diagnosis and Prognosis' Physical Examination Diagnostic Testing Noninvasive Testing Treatment' Angiotensin-Converting Enzyme Inhibitors And Angiotensin-II Receptor Blockers Meta-analyses Studies β-blockers Review Articles and Meta-analyses Carvedilol Studies Other Studies Diuretics And Aldosertone Antagonists Digoxin Vasodilators Inotropic And Other Agents Mechanical Assist Devices And Surgical Options Invasive Therapy Additional Therapeutic Considerations Anticoagulation Exercise
CHAPTER 6. Arrhythmias Benjamin A. Steinberg, Christopher P. Cannon ATRIAL ARRHYTHMIAS Epidemiology Natural History Etiologies and Risk Factors Stroke Risk Factors Treatment' Rate Versus Rhythm Control Pharmacologic Agents For Control Of The Ventricular Rate Pharmacologic Agents For The Acute Conversion Of Atrial Fibrillation Intravenous Agents Oral Agents Pharmacologic Agents For Long-Term Maintenance Of Sinus Rhythm Catheter And Surgical Ablation Catheter Ablation Surgical Ablation Electrical Cardioversion Type and Amount of Energy Anticoagulation Before and After Cardioversion Prevention Of Thromboembolism Long-Term Anticoagulation Non-Vitamin K Oral Anticoagulants Other Strategies To Prevent Thromboembolism Other Treatment Measures Atrial Fibrillation Prevention After Cardiac Surgery VENTRICULAR ARRHYTHMIAS Immediate Therapy: Automated External Defibrillators Immediate Therapy: Intravenous Amiodarone Secondary-Prevention Trials: Drugs Versus Implantable Cardioverter Defibrillators Primary-Prevention Trials: Antiarrhythmic Drugs Primary-Prevention Trials: Drugs Versus Implantable Cardioverter Defibrillators Primary-Prevention Trials: Nonischemic Cardiomyopathy Patients Studies Of emerging Tachyarrhythmia Therapies CARDIAC PACING STUDIES Pacemaker Mode Selection Trials Pacing For Vasovagal Syncope Pacing For Prevention Of Atrial Fibrillation Resynchronization Therapy For Congestive Heart Failure REFERENCES Atrial Fibrillation' Guidelines Epidemiology Risk Stratification Rate Versus Rhythm Control Drug Trials For Rate And Rhyhtm Control In Atrial Fibrillation Catheter And Surgical Ablation Catheter Ablation Surgical Ablation Electrical Cardioversion And Pericardioversion Anticoagulation Long-Term Anticoagulation Non-Vitamin K Oral Anticoagulants Non-Pharmacologic Stroke Prevention In AF Atrial Fibrillation Prevention After Surgery Ventricular Arrhythmias' Guidelines Immediate Therapy: Automated External Defibrillators Immediate Therapy: Intravenous Amiodarone Secondary-Prevention Trials: Drugs Versus Implantable Cardioverter Defibrillators Primary-Prevention Trials: Antiarrhythmic Drugs Primary-Prevention Trials: Drugs Versus Implantable Cardioverter Defibrillators Primary-Prevention Trials: Nonischemic Cardiomyopathy Patients Studies Of Emerging Tachyarrhythmia Therpaies Cardiac Pacing Studies' Guidelines Mode Selection Trials Pacing For Vasovagal Syncope Pacing For Prevention Of Atrial Fibrillation Resynchronization Therapy For Congestive Heart Failure
Index
Apply the latest knowledge on atrial fibrillation and heart failure, including novel anticoagulants, new medical therapies, new devices including ablation and resynchronization and other advanced therapies.
Select the best interventions for acute coronary syndrome with coverage of new antiplatelet strategies, management strategy updates, and significant data on outcomes and guideline adherence.
Navigate controversies across your entire field with in-depth chapters exploring all areas of preventive cardiology, coronary revascularization and percutaneous procedures, unstable angina/non-ST elevation myocardial infarction, ST-elevation myocardial infarction, heart failure, and arrhythmias.
Look up all essential randomized clinical trials and understand their implications with concise summaries of trial design, study population, treatment regimen, and results, together with relevant ACC/AHA Practice Guidelines.
Now included with the print edition, enjoy the bundled interactive eBook edition, which can be downloaded to your smartphone or tablet, or accessible online and includes features like:
Complete content with enhanced navigation
A powerful search that pulls results from content in the book, your notes, and even the web
Cross-linked pages, references, and more for easy navigation
Highlighting tool for easier reference of key content throughout the text
Ability to take and share notes with friends and colleagues
Quick reference tabbing to save your favorite content for future use
' excellent job of providing a detailed summary of clinical trials in the cardiology literature' 'useful in day-to-day clinical practice in cardiology' 'esteemed authors together have over 800 publications and book chapters between them' ' divided into sections of preventive cardiology, invasive cardiology, and acute MIs, heart failure, and arrhythmia' 'The format of the book is very helpful for getting a quick snapshot of a trial ' ' good source of information for both trainees and practitioners in cardiology' Weighted Numerical Score: 75 - 3 Stars - Doodys Publishers' Club, Friday, January 8, 2016
Your cart cannot contain products from multiple regions.
If you click continue, items in the cart from the previous
region will be removed. To keep items from the previous
region in your cart, click cancel.
This item is not related to current region.
AAOS members get an exclusive discount. Please click continue to log in as an AAOS member.
AHA members get an exclusive discount. Please click continue to log in as an AHA member.
All prices are listed in US dollars, and all purchases will be charged in US funds.